| VTE | |||||
|---|---|---|---|---|---|
| Apixaban (n = 47) |
Rivaroxaban (n = 152) |
Apixaban and rivaroxaban combined (n = 199) |
Warfarin (n = 167) |
Total (n = 366) |
|
| Age at the time of prescription (years) | 53.3 (13.9) | 52.4 (14.7) | 52.6 (14.5)* | 58.1 (15.1) | 55.1 (15.0) |
| BMI (kg/m2) | 43.3 (41.2-49.4) |
43.7 (41.1-48.8) |
43.7 (41.2-49.0)* |
45.3 (41.4-52.5) |
44.7 (41.3-50.1) |
| ≥50 | 10 (21%) | 30 (20%) | 40 (20%)* | 52 (31%) | 92 (25%) |
| Female | 35 (75%) | 100 (66%) | 135 (68%) | 118 (71%) | 253 (69%) |
| Male | 312 (25%) | 52 (34%) | 64 (32%) | 49 (29%) | 113 (31%) |
| Race | |||||
| White | 3 (6%) | 26 (17%) | 29 (15%) | 31 (19%) | 60 (16%) |
| Black | 26 (55%) | 66 (43%) | 92 (46%) | 80 (48%) | 172 (47%) |
| Other or unknown | 18 (38%) | 60 (40%) | 78 (39%) | 56 (34%) | 134 (37%) |
| Charlson score | 0.0 (0.0-2.0) |
1.0 (0.0-2.5) |
1.0 (0.0-2.0) |
2.0 (0.0-4.0) |
1.0 (0.0-3.0) |
| CHA2DS2-VASc score | NA | NA | NA | NA | NA |
| Follow-up (days) | 163.3 (90.0-233.3) |
217.4 (94.4-514.1) |
191.5 (91.5-425.3) |
206.3 (64.4-540.3) |
196.0 (89.4-457.3) |
Data are mean (SD), median (IQR), or n (%).
